Egerton joins Oxagen as CCO, board member

FRAMINGHAM (11/24/2003) - Mark Egerton, former CEO of U.K.-based Cyprotex PLC, a preclinical services company, has joined Oxagen Ltd. as its chief commercial officer and has been appointed to the board of the company. Oxagen specializes in target identification and validation in inflammatory and metabolic diseases. Meanwhile, Oxagen's former director of business development, Simon Bennett, has taken a position with Solexa Ltd., a company developing genome-sequencing technology, as its business development director.

Join the newsletter!

Or

Sign up to gain exclusive access to email subscriptions, event invitations, competitions, giveaways, and much more.

Membership is free, and your security and privacy remain protected. View our privacy policy before signing up.

Error: Please check your email address.
Show Comments
[]